Testing a new blood-cleaning device for severe liver failure

Plain-English translation of NCT07347275 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

What is this trial?

This trial is testing DIALIVE 2.0, a new liver dialysis device designed to help people with severe, acute-on-chronic liver failure. The device works by filtering your blood to remove harmful toxins and inflammatory substances that accumulate when the liver stops working properly, while also replacing healthy proteins your body needs. Half of participants will receive this new treatment in addition to standard care, while the other half will receive standard care alone.

Acute-on-chronic liver failure is a life-threatening condition where a damaged liver suddenly worsens. Standard treatments often aren't enough to save lives, so doctors are testing whether this new blood-filtering technology can remove dangerous toxins more effectively and give patients a better chance of survival.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with acute-on-chronic liver failure (grade 2-4 severity)
your condition worsened despite standard treatment for at least 48 hours before being enrolled
you are enrolled within 10 days of your liver failure becoming severe

You likely don't qualify if…

you have had severe liver failure for more than 10 days before enrollment
you are pregnant or have untreated bacterial or fungal infections
you have dangerously low blood platelet counts or severe bleeding problems
you require very high doses of blood pressure medications or are on kidney dialysis
you have severe kidney disease, uncontrolled cancer, or other serious illnesses that would make participation unsafe

What participation looks like

If you join this trial, you will either receive the new DIALIVE 2.0 treatment plus standard care, or standard care alone. If assigned to the treatment group, you will receive daily 6-to-8-hour sessions where your blood is circulated through the dialysis device to filter out toxins and inflammatory substances, with albumin and other blood proteins replaced to keep you stable. You will be closely monitored throughout the trial to track how well the treatment works and how you respond.

Testing a new blood-cleaning device for severe liver failure

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)